PhD Boštjan Markelc

PhD Boštjan Markelc
no.: 32175 source: ARIS

researcher – active in research organisation
  • English
  • Reading: Fluent
  • Writing: Fluent
  • Speaking: Fluent
Edit
Research activity

Code Science Field Subfield
3.00.00  Medical sciences     
3.04.00  Medical sciences  Oncology   

Code Science Field
B200  Biomedical sciences  Cytology, oncology, cancerology 
Bibliography Representative bibliographic units | Personal | COBISS+
source: COBISS
source: SICRIS
Evaluation (metodology)
Evaluation of bibliographic research performance indicators according to ARIS methodology
source: COBISS
source: ARIS
Points
761.24
A''
104.2
A'
474.13
A1/2
600.8
CI10
1,610
CImax
175
h10
20
A1
2.82
A3
5
Data for the last 5 years (citations for the last 10 years) on November 15, 2025; Data for score A3 calculation refer to period 2020-2024 (2020, 2021, 2022, 2023, 2024)
Data for ARIS tenders ( 21.05.2024 – Target research programmes, archive )
Citations Citations for bibliographic records in COBIB.SI that are linked to records in citation databases
source: WoS source: Scopus source: COBISS
Database Linked records Citations Pure citations Average pure citations
WoS 75  1,846  1,468  19.57 
Scopus 75  2,054  1,643  21.91 
Mentoring junior researchers
source: ARIS
no. Name and surname Type Period Code
1 Iva Šantek   Bologna doctoral studies    55825 
2 PhD Tim Božič   Bologna doctoral studies  10/1/2018 - 9/30/2022  51848 
Doctoral dissertations and other final papers Show
Obtaining results now
source: COBISS
Employments
source: ARIS
Type of employment Research org. Research group
Full time employment (100%, RD:100%)  Institute of Oncology Ljubljana  Department of research 
Research projects Legend
source: ARIS
no. Code Title Period Head
1. J3-60068  Circulating tumor cell translational research platform.   1/1/2025 - 12/31/2027  PhD Tanja Jesenko   2,997 
2. J1-60017  Perfusion, Edema, and Necrosis Evaluation using OCT for Tumor Outcome Measures   1/1/2025 - 12/31/2027  PhD Jošt Stergar   2,808 
3. J3-50108  DEBIO 1143 has a potential to increase effectiveness of electrochemotherapy and radiotherapy in HPV positive and HPV negative Head and Neck Cancers   10/1/2023 - 9/30/2026  PhD Katarina Žnidar   2,456 
4. J4-50150  Erythrocyte membrane-based nanocarriers for gene silencing cancer therapy   10/1/2023 - 9/30/2026  PhD Nina Kostevšek   4,304 
5. L3-50111  Gene immuno-therapy of solid tumors based on mRNA encoding interleukin-12: So-rIL   10/1/2023 - 9/30/2026  PhD Maja Čemažar   3,109 
6. J3-50110  Intratumoral mRNA electrotransfer: establishment and preclinical proof of concept   10/1/2023 - 9/30/2026  PhD Katja Uršič Valentinuzzi   3,451 
7. J2-50068  Safety and efficacy of high frequency electrochemotherapy - clinical device development   10/1/2023 - 9/30/2026  PhD Matej Reberšek   3,799 
8. J7-4635  MitoCan - Preclinical development of new Mitochondrial ion channel inhibitors for Cancer therapy   10/1/2022 - 9/30/2026  PhD Lucija Peterlin Mašič   6,799 
9. BI-US/24-26-093  The role of extracellular matrix in the development of normal and tumor vasculature   7/1/2024 - 6/30/2026  PhD Boštjan Markelc   282 
10. L7-4491  Development of integrated multi-channel artificial nose for detection of cancer   10/1/2022 - 9/30/2025  PhD Igor Muševič   6,032 
11. J3-4504  Uncovering the glioblastoma microenvironment to enhance the therapy   10/1/2022 - 9/30/2025  PhD Metka Novak   2,037 
12. J3-3083  Vascularization and vascular effects as predictive factors for local ablative techniques   10/1/2021 - 9/30/2025  PhD Gregor Serša   7,434 
13. BI-US/22-24-070  Demonstration of the possibility of linking results between three-dimensional biometric vessel models and tumor vessels in vivo   7/1/2022 - 6/30/2024  PhD Boštjan Markelc   282 
14. J3-2528  Immuno gene electrotransfer of IL-12 and IL-2 in immunologically cold/hot tumors   9/1/2020 - 8/31/2023  PhD Maja Čemažar   3,497 
15. J3-2529  Role of endothelium in tumor response to radiotherapy   9/1/2020 - 8/31/2023  PhD Boštjan Markelc   3,804 
16. J3-9269  Clinico-pharmacological approach to optimize the therapeutic bleomycin concentration in patients undergoing electrochemotherapy   7/1/2018 - 6/30/2021  PhD Gregor Serša   3,917 
17. J2-9225  Non-invasive technique for Cell Membrane Permeabilization using pulsed electromagnetic fields   7/1/2018 - 6/30/2021  PhD Damijan Miklavčič   3,120 
18. J3-8202  Spremljanje imunskega odziva v realnem času po in situ vakcinaciji z elektrokemoterapijo in pridruženo gensko terapijo z interlevkinom-12 (Slovene)   5/1/2017 - 4/30/2020  PhD Maja Čemažar   3,881 
19. J4-5529  Nitroksolin in njegovi derivati kot nova protitumorska zdravila (Slovene)   8/1/2013 - 7/31/2016  PhD Janko Kos   6,626 
20. J3-4259  Priprava in validacija terapevtskih plazmidov brez selekcijskega gena za antibiotično rezistenco za gensko terapijo raka z inducibilnimi in tkivno specifičnimi promotorji (Slovene)   7/1/2011 - 6/30/2014  PhD Maja Čemažar   6,412 
21. L2-4105  Razvoj programa za numerično modeliranje elektroporacije in vivo ter njegova validacija? in silico elektroporacija (Slovene)   7/1/2011 - 6/30/2014  PhD Damijan Miklavčič   5,251 
ARIS research and infrastructure programmes Legend
source: ARIS
no. Code Title Period Head
1. P3-0003  Development and evaluation of new approaches to cancer treatment   1/1/2022 - 12/31/2027 PhD Gregor Serša   4,493 
2. I0-0059  Infrastrukturna dejavnost ONKOLOŠKI INŠTITUT (Slovene)   1/1/2022 - 12/31/2027 PhD Boštjan Markelc   661 
3. P3-0003  Development and evaluation of new approaches to cancer treatment   1/1/2015 - 12/31/2021 PhD Gregor Serša   3,604 
4. P3-0003  Development and evaluation of new approaches to cancer treatment   1/1/2009 - 12/31/2014 PhD Gregor Serša   4,370 
We were not given permission by the researcher to publish data.
Confirmation required
Views history
Favourite